A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist

Journal of Allergy and Clinical Immunology

Volumn 102, Issue 1, 1998, Pages 50-56

  Altman, Leonard C ^a   Munk, Zev ^b   Seltzer, James ^c   Noonan, Nancy ^d   Shingo, Sumiko ^d   Zhang, Ji ^d   Reiss, Theodore F ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Breco Research   (United States)

^c Clinical Research Institute Inc   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Asthma; Cysteinyl leukotriene receptor antagonist; Montelukast

Indexed keywords

ANTIHISTAMINIC AGENT; ANTITUSSIVE AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CODEINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; ESTROGEN; EXPECTORANT AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PARACETAMOL; PEPTIDOLEUKOTRIENE; SALBUTAMOL; THEOPHYLLINE; THYROID HORMONE;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; IMMUNOPATHOGENESIS; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 0031871195     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(98)70054-5     Document Type: Article

References (24)

1. Dahlen SE, Hedquist P, Hammerstrom S, Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature 1980;288:484-6.
2. 4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982;126:449-51.
3. Woodward DF, Wichmann BF, Gill CA, Wassermann MA. The effect of synthetic leukotrienes on tracheal microvascular permeability. Prostaglandins 1983;25:131-42.
4. Drazen JM, Austen KF. Leukotrienes and airway responses. Am Rev Respir Dis 1987;136:985-98.
5. Labat C, Ortiz JL, Norel X, Gorenne I, Verley J, Abrams TS, et al. A second cysteinyl leukotriene receptor in human lung. J Pharmacol Exp Ther 1992;263:800-5.
6. 4-receptor antagonist. Can J Physiol Pharmacol 1995;73:191-201.
7. DeLepeleire I, Reiss TF, Rochelle F, Botto A, Zhang J, Kundu S, et al. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther 1997;61:83-92.
8. Crapo RO, Hankinson JL, Irvin C. Standardization of spirometry. Am J Respir Crit Care Med 1995;152:1107-36.
9. Santanello NC, Barber BL, Reiss TF, Friedman BS, Juniper EF, Zhang J. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J 1997;10:646-51.
10. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health-related quality of life in asthma: develop-ment of a questionnaire for use in clinical trials. Thorax 1992;47:76-83.
11. Tukey JW, Ciminera IL, Heyse JF. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 1985;41:295-301.
12. Chervinsky P, van As A, Bronsky EA, Dockhorn R, Noonan M, LaForce C, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol 1994;94:676-83.
13. Toogood JH. High-dose inhaled steroid therapy for asthma. J Allergy Clin Immunol 1989;83:528-36.
14. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150:618-23.
15. 4 antagonist, MK-679. Am Rev Respir Dis 1993;147:1442-6.
16. 4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis 1992;146:358-63.
17. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl leukotriene receptor antagonist. Lancet 1991;337:1062-3.
18. U.S. Department of Health and Human Services. National Asthma Education Program, Expert Panel Report. Guidelines for the diagnosis and management of asthma. Bethesda (MD): National Heart, Lung, and Blood Institute; 1992; Publication No. 91-3042.
19. Juniper EF, Guyatt GH, Will an A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47:81-7.
20. U.S. Department of Health and Human Services. National Heart, Lung, and Blood Institute/World Health Organization Workshop Report. Global initiative for asthma: global strategy for asthma management and prevention. Bethesda (MD): National Heart, Lung, and Blood Institute, National Institutes of Health; 1995; Publication No. 95-3659.
21. Taylor DR, Sears MR, Herbison GP, Flannery EM, Print CG, Lake DC, et al. Regular inhaled β-agonist in asthma: effects on exacerbations and lung function. Thorax 1993;48:134-8.
22. Bousquet JP, Chanez JY, Lacoste G, Barnéon G, Ghavanian N, Exander I, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990;323:1033-9.
23. Wickremasingh RG, Khan MA, Hoffbrand AV. Do leukotrienes play a role in the regulation of proliferation of normal and leukemic hemopoietic cells? Prostaglandins Leukot Essent Fatty Acids 1993;48:123-6.
24. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993;341:989-90.